
Dr Rupert D Holms: Newalr&D Ltd, London, Holds Granted Patents to Generation-3 Ezrin Peptide Therapeutics
NewalR&D Ltd, London, holds granted patents to generation-3 ezrin peptide therapeutics. Ezrin peptide technology was reverse-engineered from HIV in London in 1993, but developed in Moscow, and the first ezrin peptide product (HEP-1, Gepon) was launched on the Russian market in 2001